Previous 10 |
Akero Therapeutics (NASDAQ: AKRO ): Q2 GAAP EPS of -$2.21 misses by $1.76 . Cash and cash equivalents of $162.6M Press Release More news on: Akero Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news,
SAN FRANCISCO , Aug. 12, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today provided a bus...
Akero Therapeutics (NASDAQ: AKRO ) initiated with Buy rating and $28 (41% upside) price target at Jefferies. Shares down a fraction premarket. More news on: Akero Therapeutics, Inc., Atreca, Inc., Personalis, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you ca...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , iTunes...
Akero Therapeutics (NASDAQ: AKRO), a clinical-stage biotechnology company developing transformational treatments for people with non-alcoholic steatohepatitis (“NASH”) and other serious metabolic disorders, has closed its initial public offering, resulting in gross proceeds of ap...
The first patient has been dosed in a Phase 2a clinical trial, BALANCED , evaluating Akero Therapeutics' (NASDAQ: AKRO ) lead candidate AKR-001 for the treatment of nonalcoholic steatohepatitis (NASH). More news on: Akero Therapeutics, Inc., Healthcare stocks news, Read more ...
SAN FRANCISCO , July 2, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced the dosing...
News, Short Squeeze, Breakout and More Instantly...
Akero Therapeutics Inc. Company Name:
AKRO Stock Symbol:
NASDAQ Market:
Akero Therapeutics Inc. Website:
2024-07-09 15:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-12 10:00:04 ET Edward Nash from Canaccord Genuity issued a price target of $56.00 for AKRO on 2024-06-12 07:44:00. The adjusted price target was set to $56.00. At the time of the announcement, AKRO was trading at $23.43. The overall price target consensus is at $...
SOUTH SAN FRANCISCO, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced initiation of the ...